International immunopharmacologyAnimalsHumansDenosumabOsteoprotegerinRANK Ligand
The RANK-RANKL-OPG axis in dermatological malignancies: A systematic review.
Hamed Zartab, Dorian Maghsoodloo, Abolfazl Parsi-Moud, Mohammad Amin Ahmadi, Mohammad Rezaei Zadeh Rukerd, Hanieh Mirkamali, Alireza Firooz
Published: 202510.1016/j.intimp.2025.115624
Abstract
BACKGROUND: The receptor activator of nuclear factor kappa-B (RANK) and its ligand (RANKL) are key regulators in bone metabolism. Beyond its role in skeletal biology, RANKL has emerged as a mediator in skin immunity and tumorigenesis. OBJECTIVES: Thi…
Preview only. Read the full abstract at the source